Health
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older. The vaccine was approved following MHRA review under the international recognition procedure, which is a targeted assessment tha
About this update from Bavarian Nordic A/s
[{"type":"image","alt":"Bavarian Nordic A/S","displaySize":"","headline":null,"caption":"Bavarian Nordic A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":224,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/X7d037B4FI93H1mEWMcPsw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8b66f55ff95ddf48491741d682cbdfa0","width":224,"height":118}},"lazy":false},{"type":"horizontalRule"},{"type":"text","content":"COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.","length":371,"tagName":"p"},{"type":"text","content":"The vaccine was approved following MHRA review under the international recognition procedure, which is a targeted assessment that recognizes approvals from certain other regulatory bodies, in this case the recent approval by the European Commission. Bavarian Nordic is targeting launch of the vaccine in the UK during the summer of 2025.","length":337,"tagName":"p"},{"type":"text","content":"“Chikungunya mostly represents a risk for UK citizens traveling overseas to affected regions in the Americas, Africa and Asia, but as recent research has shown, invasive mosquitos known to carry the disease have established themselves in many parts of Southern Europe and are moving further north due to climate change1,” said Paul Chaplin, President and CEO of Bavarian Nordic. “The mosquitos cannot be stopped, but with preventative measures such as vaccines, we can mitigate the impact of emerging diseases like chikungunya for those at risk, and we look forward to launching our vaccine in the UK later this year.”","length":618,"tagName":"p"},{"type":"text","content":"The UK approval of VIMKUNYA marks the third approval of Bavarian Nordic’s chikungunya vaccine, which was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025.2,3 Bavarian Nordic has also submitted an application to Health Canada, potentially supporting approval of the chi...